A soft electronic-instrumented cardiac patch for minimally invasive delivery and tissue healing by Shin, Jane Hae Soo
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2019
A soft electronic-instrumented
cardiac patch for minimally
invasive delivery and tissue healing
https://hdl.handle.net/2144/36626
Boston University
   
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
 
A SOFT ELECTRONIC-INSTRUMENTED CARDIAC PATCH  
 
FOR MINIMALLY INVASIVE DELIVERY AND TISSUE HEALING 
 
 
 
 
 
by 
 
 
 
 
JANE HAE SOO SHIN 
 
M.S., Stanford University, 2015 
B.S., Stanford University, 2015 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2019  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2019 by 
 JANE HAE SOO SHIN 
 All rights reserved  
   
Approved by 
 
 
 
 
First Reader   
 J. Fernando Garcia-Diaz, Ph.D. 
 Associate Professor of Physiology and Biophysics 
 
 
Second Reader   
 Yu Shrike Zhang, Ph.D. 
 Assistant Professor of Medicine 
 Harvard Medical School 
 Associate Bioengineer of Medicine 
 Brigham and Women’s Hospital 
 
 
 
Third Reader   
 Jeremy N. Ruskin, M.D. 
 Professor of Medicine 
 Harvard Medical School 
 Founder and Director Emeritus of Cardiac Arrhythmia Service 
 Omran Alomran Endowed Chair in Cardiology 
 Massachusetts General Hospital 
  
  
 
 
 
 
  iv 
ACKNOWLEDGMENTS 
 
I would like to express my deepest appreciation to Dr. Shrike Zhang; thank you 
very much for your patience, constructive advice, and constant motivation. Your prompt 
responses and feedbacks helped to push the project forward. I would like to extend my 
sincere thanks to Carolina for her friendship and relentless support with the work, Feng 
for her help with taking viscosity measurements and using other equipment, and Andres 
for assembling Chihuahua, the 3D bioprinter, and modifying her in a timely manner upon 
my requests. I thank the rest of Shrike’s lab family for their love and friendship.  
 
I’m deeply indebted to Dr. Jeremy Ruskin; thank you very much for giving me 
the opportunity to shadow you and work with you and your amazing fellows. You are an 
inspiration – the charismatic and compassionate doctor, researcher, and mentor. It has 
been and will continue to be my deepest honor to work with you and learn from you. I am 
also thankful for Dr. Ruskin’s research fellows (Xuejing, Pablo, Ayman, Uwajah, and 
Jen) for their friendship and Dr. Leon Ptaszek for his guidance.  
 
The completion of this thesis and the MAMS program wouldn’t have been 
possible without Dr. Garcia-Diaz, my first reader and advisor, and Dr. Offner. The 
cardiovascular physiology Dr. Garcia taught me has inspired me to look into the field and 
explore. Dr. Offner’s unparalleled support has motivated me to constantly push myself.  
 
  v 
My eternal cheerleader, Noriko: you have seen me at my worst and at my best, 
and you have always trusted me, listened to me, and never judged me once. You are my 
pillar of strength and conscience. I especially appreciate your brutal honesty when I don’t 
make the best decisions for myself.  
 
Last but not least, I couldn’t be who I am and where I am now without you all: 
my parents, sister, and Jerry. Jerry, I pray for your full recovery every day. Thank you for 
everything. 
 
  
  vi 
A SOFT ELECTRONIC-INSTRUMENTED CARDIAC PATCH  
 
FOR MINIMALLY INVASIVE DELIVERY AND TISSUE HEALING 
 
 
JANE HAE SOO SHIN 
ABSTRACT 
 
Engineering cardiac tissues has attracted increasing attention in regenerative 
medicine. Human cardiac tissue has a complex and unique structure with intricately 
embedded vasculature network, making engineering cardiac tissue a challenge. This work 
aims to ultimately use three-dimensional (3D) extrusion bioprinting to engineer a 
myocardium that closely mimics the structure of its native counterpart with an embedded 
sensor for monitoring. We have specifically optimized the bioprinting parameters and the 
bioink composition. We also modified surface chemistry in order to bind two different 
materials. This provides a way to chemically attach the sensor mesh to a bioprinted 
cardiac construct. The developed cardiac patch can be used to replace the damaged or 
diseased cardiac tissues with the potential for non-invasive monitoring.  
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INTRODUCTION 
 
Tissue and organ failure as a consequence of an injury or a disease is a major 
healthcare challenge (Persidis 1999; Langer and Vacanti 1993). Compounding this is the 
limited availability of donor tissues and organs for transplantation, making the demand 
for engineered tissues higher (Khademhosseini et al. 2006; Kang et al. 2016). The field of 
tissue engineering is an interdisciplinary collaborative effort involving physical sciences, 
life sciences, and engineering and aims to restore, regenerate, or enhance dysfunctional 
and impaired tissues and organs (Langer and Vacanti 1993; Shafiee and Atala 2017). The 
potentials of the field are far broader; with engineering tissues or whole organs, drug 
development can be accelerated and the demand for organ donors may decrease.  
 
In the early 1990s, Langer and Vacanti first described the concept of the field and 
the scaffold-based approach. Tissues are regenerated in vitro by injecting cultured cells in 
a scaffold. Scaffolds are biocompatible and porous structures that may house growth 
factors as well as physical and chemical cues that support cell growth. When cell-seeded 
scaffolds are implanted at the target site, cells proliferate, differentiate, and migrate 
within the matrix, creating its own three-dimensional (3D) micro-architecture, while the 
scaffolds are degraded and completely absorbed at a matching rate (Nakamura et al. 
2010; Langer and Vacanti 1993; Griffith 2002; Khademhosseini et al. 2006). The crux of 
tissue engineering is to reproduce the complex, intricate microstructure of extracellular 
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matrix (ECM) to support multiple cell types and to mimic the native micro-architecture 
of a tissue. 
 
Engineering Challenges of Tissue Engineering 
The scaffold-based approach has a major disadvantage proved to be a great hurdle 
for the field. In this approach, the solution of cells and growth factors that are injected 
into 3D scaffolds is homogenous, thereby injected materials are distributed randomly 
and, more or less, evenly throughout (Nakamura et al. 2010). This is starkly different 
from the native counterpart where physiological processes are regulated by spatially 
controlled physicochemical signals. For example, chemotaxis or cellular movement is 
dependent on the gradient of molecules in the ECM (Rozario and DeSimone 2010; Jeon 
et al. 2002; Shamloo et al. 2008).  
 
Designing scaffolds that closely mimic the physical, chemical, and mechanical 
properties of ECM is crucial for cell proliferation and differentiation and tissue 
morphogenesis and homeostasis (Chung et al. 2005; Khademhosseini et al. 2006; Sant et 
al. 2010). Although the fundamental composition of the ECM is polysaccharides, water, 
and proteins, the ECM of every tissue has a unique composition and 3D topology (Frantz, 
Stewart, and Weaver 2010). This distinctiveness is responsible for cell-to-cell and cell-to-
environment interaction and signaling and cell migration (Figure 1). Scaffolds are 
biocompatible and porous and can be seeded with growth factors and other biomolecules 
(Shafiee and Atala 2017; Griffith 2002). The engineering parameters considered are pore 
sizes, permeability, and spatial distribution of biological factors, among others (Shafiee 
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and Atala 2017; Khademhosseini et al. 2006; Mahoney and Saltzman 2001). The 
appropriate biomaterials for fabrication of scaffolds can be synthetic or natural but must 
allow interaction with specific adhesion and growth factor receptors on cells from the 
target site like the native ECM (Griffith 2002). There is a need for a fabrication method 
that allows precise spatial and temporal organization of biomaterials. 
 
Figure 1. Schematics of cell-cell contacts, cell-ECM interactions, and 
physicochemical gradients in vivo. A: Cell-cell contact and cell-ECM interactions 
generate chemical gradients that affect cell behaviors such as cell proliferation, 
migration, and differentiation. B: Chromosomes generate a Ran-GTP gradient that 
organizes the mitotic spindle during cell division. C: A steep gradient is seen by one end 
of the cell results in elongation whereas a mild gradient seen by the whole cell results in 
branching. D: Mesenchymal stem cells (MSCs) sequentially differentiate into osteoids 
and calcified bone cells in response to the graded signals in the ECM (Adapted from Sant 
et al. 2010). 
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Hydrogels are a network of hydrophilic, water-swollen, cross-linked polymer 
chains with mechanical properties that closely resemble living tissue; the degree of 
hydrogel swelling is closely related to its mechanical strength (Zhang and 
Khademhosseini 2017; Peppas et al. 2000). Their mechanical properties can be altered by 
changing the comonomer composition, altering the cross-linking condition, and changing 
cross-linking density (Van Vlierberghe, Dubruel, and Schacht 2011). The synthetic 
hydrogels (e.g. poly(ethylene glycol) and poly(vinyl alcohol)) have highly flexible 
mechanical and chemical properties that can be optimized, but often lack biological 
moieties vital for cell survival and communication (Noshadi et al. 2017). The natural 
hydrogels (e.g. hyaluronic acid, chitosan, and alginate) are biodegradable and 
biocompatible with functional biological moieties, but lack optimal mechanical properties 
and are difficult to modulate their degradation profile and functions (Noshadi et al. 2017). 
Among these, gelatin methacryloyl (GelMA) has been gaining interest. It is modified 
from gelatin, a hydrolyzed product of collagen. Collagen is the most abundant fibrous 
protein in ECM; 30% of the total protein mass of a multicellular animal is collagen 
(Frantz, Stewart, and Weaver 2010). Naturally, gelatin has a large variety of side chains 
for cellular functions and for chemical modification for other application such as drug 
delivery (Van Vlierberghe, Dubruel, and Schacht 2011). GelMA was first characterized 
by Van Den Bulcke and has been since shown that subcutaneous injection of GelMA 
hydrogel promotes in vitro vascularization and tissue formation (Van Den Bulcke et al. 
2000; Noshadi et al. 2017). GelMA hydrogels have potential as biomaterials for an ideal 
scaffold, which should be biocompatible, and possibly biodegradable, have mechanical 
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properties of a target tissue, and mimic the external and internal configurations with 
precisely orchestrated biomolecules (Yin et al. 2018; Shafiee and Atala 2017). 
 
In addition, the vascular supply needs to be provided for engineered tissues 
because the diffusion of oxygen from a given blood vessel is limited to 100-200 µm 
(Carmeliet and Jain 2000). Angiogenesis, or new blood vessel formation, takes several 
days to develop to support newly implanted tissues. It was shown that the cells implanted 
for bone or tendon repair could not exploit the native vasculature source (Richardson et 
al. 2001; Khademhosseini et al. 2006). Lack of sufficient vascularization has led to 
nutrient deficiencies and hypoxia, affecting the viability of implanted tissues 
(Rouwkema, Rivron, and van Blitterswijk 2008). However, the existing microvasculature 
in a small bone tissue implant facilitated the delivery of blood and nutrients from the host 
blood vessels at the injury site (Black et al. 1998). Hence, the use of endothelial cells for 
introducing a microvascular network in engineered tissues is a promising strategy for 
providing vascular supply. 
 
Bioprinting has emerged as a potentially powerful approach to overcome some of 
the challenges associated with conventional biofabrication strategies. This approach can 
address building a tissue with a complex 3D microenvironment, multiple cell types, dense 
cell populations, and even possibly embedded vasculature (Figure 2). 
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Figure 2. Requirements for bioprinting technologies to successfully manufacture 
biological tissues and organs (Adapted from Nakamura et al. 2010). 
 
 
3D Bioprinting  
In 1986, Charles W. Hull developed “stereolithography,” a layer-by-layer printing 
of materials that are cured with ultraviolet light to eventually form a 3D object (U.S. 
Patent No. 4575330, 1984). The 3D printing methods were later adapted to directly print 
biological materials for tissue engineering. The bioinks can be printed in layers (e.g. 
stereolithography), in continuous lines (e.g. microextrusion), or in droplets, also known 
as drop-on-demand (e.g., inkjet bioprinting) (Blaeser, Duarte Campos, and Fischer 2017) 
(Figure 3). The stereolithography method uses dynamic photomasks to define the curing 
pattern of each layer of photocrosslinkable bioinks with a high degree of resolution 
(Blaeser, Duarte Campos, and Fischer 2017). In inkjet bioprinting, a single drop 
containing a controlled volume of bioinks is deposited onto a substrate, which allows for 
control over spatial orientation. The droplets can be ejected by thermal heating or 
acoustic forces (e.g. deformation of piezoelectric crystal). In microextrusion bioprinting, 
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the bioink is ejected through a needle by pneumatic or mechanical (e.g. piston or screw) 
forces (Blaeser, Duarte Campos, and Fischer 2017; Murphy and Atala 2014). 
 
The different classes of bioprinting methods offer advantages and disadvantages. 
The drop-on-demand method offers low-cost, high-resolution, and high-speed 
bioprinting. It can also create a concentration gradient of cells, growth factors, or 
biomaterials by varying the density and the size of droplets. In addition, the extrusion 
bioprinting is the most commonly used and affordable. It is compatible with a wide range 
of fluid properties such as viscosities and thus, able to deposit high or close-to-
physiological cell densities. For both classes of bioprinting, photocrosslinking via 
ultraviolet (UV) light is often used as gelation of bioinks, and thus crosslinking 
mechanisms can be toxic to cells and negatively affect cell viability and functionality. In 
addition, the dispensing nozzle from which the ink is ejected can get clogged depending 
on its viscosity. There are also risks of exposing cells and biomaterials to mechanical or 
thermal stresses, which can affect the cell viability and functionality (Blaeser, Duarte 
Campos, and Fischer 2017; Murphy and Atala 2014).  
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Figure 3. Overview of different 3D bioprinting techniques (Adapted from Blaeser, 
Duarte Campos, and Fischer 2017). 
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3D Bioprinting on Cardiac Application 
Engineering solid organs such as heart, kidney, and liver are tremendously 
challenging because of the need for vascularization and structures that can support 
multiple cell types and organize cells into their native 3D architecture to carry out the 
desired functions (Maher 2013). The heart is essential for the delivery of nutrients and 
oxygen and removal of waste products to all organs through the vasculature. 
Cardiovascular diseases are the leading causes of deaths worldwide (Perreault et al. 
1990). Owing to mature cardiomyocytes’ limited regenerative capability, the heart is one 
of the top needed organs for transplantation after kidney and liver. (Maher 2013). 
However, donors’ hearts are rare because they are often damaged from disease or 
resuscitation efforts (Maher 2013; Ott et al. 2008). Hence, bioengineering cardiac tissues 
for transplantation is strongly desired. In addition, it has been reported that 19% of the 
drugs over the last 40 years have been withdrawn in the United States because of adverse 
cardiac toxicity (Piccini et al. 2009). Thus, developing a cardiac tissue model for drug 
testing is increasingly gaining attention. 
 
The heart organogenesis begins with endocardial and myocardial precursors from 
lateral splanchnic mesoderm. These cells coalesce and fuse to form a primitive heart tube, 
consisting of epithelial endocardium surrounded by an epithelial tube of the myocardium. 
The tube undergoes the process of looping in which the four chambers of the heart and 
the valves precursors form as well as the three layers of the heart, epicardium, 
myocardium, and endocardium, are established (Smith and Bader 2007). The cell-to-cell 
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signaling is crucial during the development; for example, during the looping, 
myocardium induces endocardial cells to migrate and differentiate into a valvular 
structure (Smith and Bader 2007). A subpopulation of epicardium differentiates into 
mesenchymal cells that evolve to the cardiac fibroblasts of coronary vessels, smooth 
muscle, and vascular endothelium (Mikawa and Gourdie 1996). The endocardium mostly 
consists of endothelial cells lining the four chambers and the valves; the myocardium is 
mostly cardiomyocytes generating pumping force, and the epicardium is rich with 
intricately embedded vascular networks (Zhang et al. 2015; Smith and Bader 2007). 
 
The heart originates from a complex organogenesis process that leads to multiple 
laminar tissues with a precise organization and bundles of cardiomyocytes. Two specific 
works on the fabrication of cardiac biomimetic constructs are discussed in the following 
sections. 
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A Bioprinted Endothelialized Heart-on-a-Chip Device 
Zhang, Khademhosseini, and colleagues developed a novel 3D bioprinting 
technique that generates stable multilayered hydrogel scaffold and fabricated an 
endothelialized-myocardium-on-a-chip platform for potential drug toxicity testing (Zhang 
et al. 2016). The myocardium-construction strategy involved bioprinting a microfibrous 
scaffold composed of GelMA, alginate, and photoinitiator with human umbilical vein 
endothelial cells (HUVECs) (Figure 4B). The bioprinted scaffold was first physically 
crosslinked with CaCl2 solution that was extruded from a coaxial nozzle simultaneously 
with the bioink. Then the endothelial cells-seeded scaffold was chemically crosslinked 
via 30 seconds of exposure to the UV light. The construct was cultured in endothelial 
growth medium for approximately 14 days before it was seeded with neonatal rat 
cardiomyocytes (Figure 4C). The fully constructed endothelialized-myocardium-on-a-
chip platform persistently contracted at 50 to 70 bpm for at least two weeks within the 
bioreactor the team built that supplied oxygen and nutrients. 
 
The group introduced anisotropic arrangements of cardiomyocytes by printing a 
grid shape with different aspect ratios of rectangles and found, with statistical 
significance, that greater anisotropic scaffold yielded highly unidirectionally aligned 
cardiomyocytes and higher connexin-43 expression. Connexin-43 is one of the proteins 
necessary for cardiac contractility as its reduced expression levels in the ventricle is 
implicated in human congestive heart failure (Severs et al. 2004). 
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Figure 4. Schematics of bioprinting strategy. A: Photograph of an Organovo Novogen 
MMX bioprinter. B: Schematic of the coaxial needle where the bioink is delivered from 
the core and the ionic crosslinking CaCl2 solution is sheathed on the side. C: Schematics 
showing the procedure of fabricating endothelialized myocardium using the 3D 
bioprinting strategy. Step 1: bioprinting of a microfibrous scaffold using a composite 
bioink encapsulating endothelial cells. Step 2: formation of the vascular bed through 
migration of HUVECs to the peripheries of the microfibers. Step 3: seeding of 
cardiomyocytes into the interstitial space of the endothelialized scaffold. Step 4: 
formation of engineered endothelialized myocardium structurally resembling the native 
myocardium (Adapted from Zhang et al. 2016). 
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The team further used the construct to do initial drug testing with a common anti-
cancer drug, doxorubicin. Doxorubicin intercalates into DNA strands and causes myriads 
of downstream detrimental effects including inhibition of protein synthesis, generation of 
reactive oxygen species, and cardiomyopathy (Chatterjee et al. 2010). The construct 
showed a concentration-dependent response to doxorubicin; beating rate progressively 
dropped with increasing dose of doxorubicin. This work lucidly illustrates 3D-bioprinted 
myocardium that closely mimics its native counterpart by showing the anisotropic 
architecture, beating, embedded microvasculature, and dose-dependent response to a 
drug. 
 
A Fully Printed Multi-layered Cardiac Microphysiological Device 
Most previous biomimetic cardiac chips required multiple lithographic processes 
to construct microcantilevers and depended on optical tracking system on a microscope to 
measure the deflection of the device resulting from contracting cardiomyocytes (Wang et 
al. 2014; Boudou et al. 2012). However, multiple manufacturing processes and optical 
tracking analysis are not ideal for high throughput studies. Parker and his team fabricated 
a fully printed multi-layered cardiac microphysiological device, which includes strain 
gauge sensors and cardiomyocyte-guiding layers, from six inks in one manufacturing step 
(Lind et al. 2017).  
 
Dextran films are printed first as a sacrificial release layer from which the 
cantilever printed on top can deflect away from (Figure 5C). Then the strain gauge wires 
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were printed using dilute thermoplastic polyurethane (TPU) inks containing 25 wt% 
carbon black nanoparticles (Figure 5E). Afterward, a layer of polydimethylsiloxane 
(PDMS) was printed in grooves as a tissue-guiding layer (Figure 5G). The team found 
that the groove spacing of 60 µm provided the highest degree of anisotropic sarcomere 
alignment as seen from confocal images. Lastly, electrical leads and contact pads were 
deposited in a silver particle-filled polyamide ink (Figure 5H). The devices were seeded 
with either neonatal rat ventricular myocytes (NRVMs) or human induced pluripotent 
stem cell-derived cardiomyocytes (hiPS-CMs). 
 
The contractile stress continuously measured by the printed strain gauge wires 
were highly similar to data obtained from optical imaging of cantilever deflection. The 
drug dose studies were carried out using an L-type calcium channel blocker, verapamil, 
and a beta-adrenergic agonist, isoproterenol. The expected negative inotropic and 
chronotropic response to the drugs were observed, respectively (Lind et al. 2017). 
 
This work not only built a single layer of cardiac myocardium that responds to 
drugs similar to its native counterpart but also successfully embedded soft electronics to 
the cardiac biomimetics that can constantly provide feedback on the electrical signals of 
the construct. Engineering a tissue construct with an encapsulated device, which can 
monitor the functional status of the construct, is a promising alternative for non-invasive 
monitoring after transplantation. 
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Figure 5. Device principle and microscale 3D-printing procedure. A: Principle sketch 
of the device. Contraction of an anisotropic engineered cardiac tissue (1) deflects a 
cantilever substrate (2), thereby stretching a soft strain gauge embedded in the cantilever. 
This generates a resistance change proportional to the contractile stress of the tissue (3). 
B: The fully printed final device. Inset 1: Confocal microscopy image of immuno-stained 
laminar NRVMs cardiac tissue on the cantilever surface. Blue: nuclei stain, White: α-
actinin, scale bar 10 μm. Inset 2: Still images of a cantilever deflecting upon issue 
contraction. Insert 3: Example resistance signal. (c–i) Automated printing of the device 
on a 2-inch x 3-inch glass slide substrate in 7 sequential steps. For each step, a 
corresponding still image from the printing procedure is displayed. For steps 1–5, a stylus 
 16 
profiling cross-sectional contour of the cantilever is additionally displayed. C: In print 
step 1, a 0.5 μm Dextran thin film sacrificial layer is printed. D: In print step 2, a 3 μm 
TPU thin film cantilever base is printed. E: In print step 3, a 6.5 μm thick CB:TPU strain 
sensor loop is added to cantilever base. F: In print step 4, a 1.5 μm TPU wire cover is 
added. G: In print step 5, 20 μm tall, 60 μm wide PDMS micro-filaments are printed in 
slightly overlapping lines. The filaments constitute the top part of the cantilever and 
guide cardiomyocytes to form anisotropic laminar tissues. H: In print step 6, electrical 
leads and contacts are added using a high conductivity Ag:PA ink. I: In print step 7, 
covers to insulate exposed wires and wells to contain cells and media are printed using 
PDMS, PLA or ABS (Adapted from Lind et al. 2017). 
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SPECIFIC AIMS 
 
 
The heart is essential for the delivery of nutrients and oxygen and the removal of 
cellular and metabolic wastes through the circulatory system. Cardiomyocytes transmit 
electrical signals through the heart that result in synchronized contractions of the 
ventricles which in turn allow the heart to pump blood efficiently throughout the body 
(Golob, Moss, and Chesler 2014). However, the previous studies indicate that 
mammalian cardiomyocytes are postmitotic and have a limited proliferative capacity (van 
Berlo and Molkentin 2014). The scar tissue formed after myocardial infarction seems 
permanent and thus, the loss of cardiomyocytes from myocardial infarction (MI) or other 
cardiovascular disease is the major cause of morbidity worldwide. Owing to this, the 
tissue engineering field has focused on the healing of a diseased or an injured heart 
through cardiomyocyte regeneration. 
 
The advent of 3D bioprinting technology allows for improved capacity in the 
engineering of cardiac tissues. Nevertheless, there are numerous engineering challenges 
for mimicking the mammalian heart tissue, particularly the alignment and bundling of 
native cardiomyocytes that allow for synchronous contraction and intricately embedded 
vascular network  (Y. S. Zhang et al. 2016, 2015). Monitoring the status of tissue 
integration is another major challenge upon implantation. The soft electronic devices can 
give feedback on physiological parameters during monitoring tissue integration. 
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The overarching goal of this work is to construct a soft electronics-instrumented 
cardiac patch for minimally invasive delivery and tissue healing. The specific aims of this 
thesis include: 
 
1. Optimizing bioprinter parameters to allow continuous printing and generate a 
structurally sturdy and stable construct. 
2. Optimizing bioink composition to obtain the viscoelasticity and pore size optimal 
for cardiac tissue construction. 
3. Constructing a hydrogel and elastomer hybrid by modifying the surface of an 
elastomer. 
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METHODS 
 
Preparation of GelMA 
GelMA was synthesized following an established protocol (Shirahama et al. 
2016). The powdered gelatin from porcine skin (Sigma-Aldrich) was added to phosphate-
buffered saline (PBS) at a 10% (w/v) concentration. The solution was stirred with a 
magnetic bar and heated at 50 ℃ until it was fully dissolved. Methacrylic anhydride was 
added at a 50% (w/v) concentration dropwise. The reaction proceeded for 2 hours at 50℃ 
and was stopped by adding PBS buffer to a final volume that is twice the original 
volume. The mixture was dialyzed with dialysis tubes (12-14 kDa; Fisher Scientific) 
against deionized water for a week. The deionized water was changed twice a day every 
day for 1 week. After the dialysis, the solution was filtered and frozen for two days. Then 
it was lyophilized at -51 ℃ and 133x10-3 Mbar. The final product, freeze-dried GelMA, 
resembles white porous foam.  
 
To prepare bioink containing, GelMA was mixed with distilled water containing 
0.5% (w/v) 2-hydroxy-1-(4-(hydroxyethoxy)-phenyl)-2-methyl-1-propanone (Irgacure 
2959, Sigma-Aldrich) as the photoinitiator and gelatin from porcine skin at the desired 
concentration. After the GelMA-containing bioink was bioprinted or poured into an 
acrylic mold, the solution was exposed to UV light (OmniCure S2000; 50 mW/cm2) and 
a source-sample distance of 7 cm for 1 minute. 
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Preparation of PDMS 
The PDMS prepolymer was purchased from Dow Corning Corporation 
(SYLGARDTM 184 Silicone Elastomer Kit). The silicone elastomer base was mixed with 
its curing agent at a ratio of 14:1. The mixture was poured onto a scaffold made of acrylic 
and was degassed in vacuum before it was baked in the 80 ℃ oven overnight.  
 
Surface Chemical Modification and Hydrogel on Elastomer Hybrid 
The surface of PDMS was conjugated with 3-(trimethoxysilyl)propyl 
methacrylate (TMSPMA) group to be able to bond to GelMA by following a published 
protocol (Zhang et al. 2014). The PDMS substrate was thoroughly washed with deionized 
water and 70% ethanol solution and was air-dried. The PDMS substrate was oxidized by 
air plasma (Harrick Plasma PDC-001 Oxygen Plasma Cleaner) for 90 seconds then it was 
immediately immersed in H2O/H2O2/HCl solution with a volume ratio of 5:1:1 for 5 
minutes. The substrate was thoroughly rinsed with deionized water and air-dried. Then it 
was immersed in a 1.5% TMSPMA solution in ethanol/H2O with a volume ratio of 1:1 
for 1 hour. The TMSPMA-treated substrate was used within a day of preparation.  
 
Contact Angle Measurement 
On freshly prepared TMSPMA-treated PDMS slides, 50 µL of deionized water 
was dropped on the surface. A frontal view picture was taken and analyzed on ImageJ. 
The statistical analysis was conducted using unpaired t-tests and for three independent 
samples per group. Statistical significance was determined at p < 0.05.  
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Viscosity Measurement 
A 1L of each sample was prepared and the viscosity was measured with 
Discovery HR-3 Hybrid Rheometer (TA instruments). The shear viscosity of various 
bioinks was obtained at 25℃, and the measurement was performed at shear rates from 
0.1 to 1000 s-1 with a gap size of 1.0 mm. 
 
Bioprinting Process 
A commercial Anet A8 3D printer (Shenzhen Anet Technology Corporation) was 
assembled and customized. The belt axis tensioner was added to improve the stability of 
the frame and generate high-quality plastic 3D prints. When the improvements generated 
high-resolution prints, a plastic adapter for a bioink syringe was printed and attached to 
the printer. The pneumatic parts were manufactured to deliver compressed air to the 
syringe.  
 
The modified Anet A8 3D bioprinter is an extrusion printer. A 27G needle (OD: 
410µm; ID:210µm) was used to deposit the bioink. The bioink used for the bioprinting 
was composed of GelMA mixed with distilled water containing 0.5% (w/v) 2-hydroxy-1-
(4-(hydroxyethoxy)-phenyl)-2-methyl-1-propanone (Irgacure 2959, Sigma-Aldrich) as 
the photoinitiator and gelatin from porcine skin at the desired concentration. After the 
GelMA-containing bioink was bioprinted, the construct was crosslinked by being 
exposed to UV light (OmniCure S2000; 50 mW/cm2) and a source-sample distance of 7 
cm for 1 minute for stable gelation. To avoid clogging during the bioprinting and extrude 
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continuous line of bioink, the bioink composition was optimized by varying GelMA and 
gelatin concentration. The 4-by-4 grid of multiple layers was printed with a dimension of 
2 mm x 2 mm x 0.75 mm. The two parameters of bioprinting, extrusion pressure, and 
nozzle speed were optimized for stable, continuous bioprinting. In this work, the m/n% 
GelMA/gelatin bioink indicates that GelMA and gelatin are m% (m/v) and n% (w/v), 
respectively. 
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RESULTS 
 
 
Printability of GelMA/Gelatin Hydrogel Bioinks 
A bioprinter (Anet A8) that was assembled in the lab was used (Figure 6A). A 
27G needle was used to extrude the bioink. The bioink used was a mixture of gelatin 
from porcine skin, GelMA, and photoinitiator dissolved in distilled water. A series of 
straight horizontal filaments with a length of 2 mm and a spacing of 2.5 mm were printed 
during optimization (Figure 6B). The structure was scripted in gcode after being drawn in 
CAD software. The printed construct was crosslinked via UV exposure.  
 
The two parameters of the bioprinter, the pressure of extrusion and the feed rate 
of the bioprinting nozzle, were optimized to obtain the constant extrusion flow and the 
structural integrity of the bioprinted structure. The pressure of extrusion was limited by 
maximum pressure of the control valve on the compressed air tank, which was 60 psi. 
The range of pressure tested was from 30 to 60 psi at a 10-psi interval. It was manually 
set by the control valve (Figure 6A). The feed rate of the nozzle was coded in the gcode 
script. The range tested was from 20 to 400 mm per minute. 
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Figure 6. Optimization of bioprinting. A: The customized Anet A8 extrusion bioprinter 
used in this work. The left circle is the pressure control valve, and the right circle is the 
extrusion nozzle. B: The bioprinted structures for bioprinting and bioink optimization. C: 
The viscosities of the bioinks used as a function of shear rate. D: The printability map of 
different bioinks tested at room temperature (23.63 ± 0.52 ℃). Printable bioinks yielded 
continuous extrusion of the bioink and stable structure without clogging the nozzle. 
Undesired bioinks needed too much temperature alterations to be able to print. Not 
printable bioinks were not viscous enough to print. E: Various shapes that were 
bioprinted. 
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The pressure of extrusion was proportional to the amount of bioink ejected from 
the nozzle. There was a minimum threshold for the extrusion pressure that depended on 
the viscosity of the bioink; regardless, 20 psi was below the threshold and no printing was 
possible with all of the bioinks tested. Nevertheless, at too high pressure, the printed 
structure was too thick and the spacings between the filaments were not visible (Figure 
6B). In addition, changing the feed rate of the nozzle affected the quality of bioprinting. 
At high speed, the structure became discontinuous (Figure 6B, Pressure of 30 psi and 
Nozzle Speed of 400 mm/min for 5/0% GelMA/Gelatin Bioink). In contrast, at low 
speed, the bioink coiled up before being deposited and created a coiled, wrinkled 
structure.  
 
The bioink composition was also optimized by varying GelMA/gelatin ratio to 
obtain a viscosity that allowed constant extrusion without clogging the nozzle and 
maintained the structural integrity of the bioprints. GelMA concentration was varied 
between 5 and 7% (w/v), while gelatin concentration was varied among 0, 2, and 5% 
(w/v). Pure GelMA bioink (5% and 7% in distilled water) remained liquid at room 
temperature, which was measured to be 23.63 ± 0.52 ℃. Gelatin was used to vary the 
viscosity of the bioink; increasing gelatin concentration increased the viscosity of bioink 
(Figure 6C). At low GelMA/gelatin ratio (no or low gelatin), the ink became too liquid to 
maintain the structure and the filaments coalesced with the adjacent filaments into a 
“blob”. However, very highly viscous bioink had a higher threshold of extrusion pressure 
and often clogged the nozzle. The 3D bioprinting parameters tested are listed in Table 1. 
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Table 1. Bioprinting parameters. 
Parameter Range 
GelMA concentration (% w/v) 5, 7 
Gelatin concentration (% w/v) 0, 2, 5 
Extrusion pressure (psi) 30-60 
Nozzle XY extrusion speed (mm/min) 20-400 
Nozzle inner diameter (µm) 210 
UV exposure time (min) 1 
UV-sample distance (cm) 7 
Bioprinting temperature (℃) 23.63 ± 0.52 ℃ 
 
The printability of the bioprinting parameters and the bioinks were assessed by 
visually inspecting the thickness, the shape, and the continuity of the printed filaments. 
An ink was printable if it produced regular and smooth fibers. A “printable with poor 
resolution” ink yielded a spindle-shaped filament that had a non-uniform thickness over 
the x-axis. An “unprintable” ink yielded either a discontinuous printing or a “blob.”  
 
GelMA and gelatin are both temperature-sensitive; the molecules can undergo 
reversible thermal crosslinking and become gelated near room temperature (Yin et al. 
2018). Most of the bioinks needed small alterations of their viscosity by short incubation 
in the ice bath or hot water bath. Nevertheless, 5% (w/v) GelMA and 5% (w/v) gelatin 
bioink produced the most optimal viscosity at room temperature that allowed a wide 
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range of conditions of bioprinting without significant tinkering of the bioink temperature 
(Figure 6D).  
 
The printability maps for different bioinks under varying bioprinting parameters 
are shown in Figure 7. The extrusion pressures of 40 and 50 psi and the bioprinting 
speeds between 200 and 300 mm/min produced the most bioprintable constructs. 
Although the 5/2% GelMA/gelatin bioink was printable under many conditions, the 
bioink required much more tinkering of the bioink temperature, often, an ice-bath 
incubation, than 5/5% GelMA/gelatin did at the room temperature (Figure 6D, Figure 7). 
Various shapes can be designed on CAD software and be bioprinted (Figure 6E). 
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Figure 7. Printability maps of different bioinks under different printing parameters. 
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Viscosities of Bioinks 
The viscosity of bioinks was measure with respect to the GelMA/gelatin ratios. 
All bioinks showed shear-thinning behavior at 25℃, near room temperature, and the 
highest GelMA and gelatin composition ink (7/5% GelMA/gelatin) showed the most 
drastic shear-thinning behavior. Increasing GelMA composition increased the viscosity of 
the ink. Seeing that 7/0% GelMA/gelatin ink had a higher viscosity than 5/2% 
GelMA/gelatin ink, increasing GelMA concentration may have a more pronounced effect 
on viscosity then increasing gelatin alone. Alternatively, increasing gelatin increased the 
viscosity by a factor of ten for the bioinks containing 5% (w/v) GelMA, whereas the 
viscosity increased by a factor less than ten for the bioinks containing 7% (w/v) GelMA, 
implying that the viscosities of 7% (w/v) GelMA bioinks are closer to the highest 
possible viscosity for low GelMA composition bioinks.  
 
Surface Modification of PDMS 
PDMS-based elastomer often serves as a substrate or carrier of highly soft, 
stretchable electronics (Jeong et al. 2016). The surface of PDMS is hydrophobic, and it 
needs to be modified to be hydrophilic in order to bind to a hydrogel (Zhang et al. 2014). 
To test the hydrophilicity of a surface of a material, one can measure the contact angle of 
a water droplet on the surface. First, a thin layer of PDMS was coated on a glass slide by 
spin-coating. Then the schematics of the surface modification on the PDMS substrates 
are shown in Figure 8. The surface of a PDMS was oxidized with oxygen plasma, which 
introduced a hydroxyl group. The generated hydroxyl groups were exposed to the surface 
by treating the surface with H2O/H2O2/HCl solution. Then the surface was silanized with 
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TMSPMA, which introduces carbon-carbon double bonds that can be cross-linked with 
methacrylate group on GelMA via UV exposure. The TMSPMA treatment generates a 
hydrophilic surface. On an untreated PDMS surface, the water contact angle was 
74.9°±3.4. After the TMSPMA treatment, the contact angle decreased to 40.1°±3.3 
(p=0.0002), showing that the hydrophilicity of the PDMS surface has increased (Figure 
9). 
 
 
 
Figure 8. Schematics of PDMS surface modification. (Adapted from Zhang et al. 
2014). 
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Figure 9. Surface contact angle of PDMS. Water contact angles on A: unmodified 
PDMS layer. B: TMSPMA-modified PDMS layer. C: comparison of untreated 
(unmodified) PDMS and treated (TMSPMA-modified) PDMS (p<0.001). 
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DISCUSSION 
 
The 3D bioprinting technology has proved advantageous for its precise spatial 
control and high resolution. The requirements of biomaterials fed in the bioprinter are 
processability that allows for smooth, high-resolution bioprinting and cytocompatibility 
to promote cell proliferation and function (Yin et al. 2018). Extrusion bioprinting was 
used in this work for its capability to manufacture an intricate microarchitecture in a 
layer-by-layer manner and for generation of porous, fibrous biomaterials to mimic the 
ECM.  
 
One of the main challenges of tissue engineering is to find a right biomaterial to 
recapitulate the native cellular environment and thereby the tissue function. GelMA is 
recently attracting more interest for its mechanical tunability, porosity, biocompatibility, 
and methacryloyl side group advantages (Yin et al. 2018; Van Den Bulcke et al. 2000). It 
is derived from gelatin, a product of hydrolytic degradation of naturally-occurring 
collagen by conjugating methacryloyl group at lysine and hydroxyl residues. Hence, 
GelMA has the advantages of gelatin: tunable physicochemical properties, RGD 
sequences for cell-to-matrix interaction, and many chemically cross-linkable functional 
side groups (Van Den Bulcke et al. 2000; Noshadi et al. 2017; Pepelanova et al. 2018). 
Gelatin can undergo reversible gelation near room temperature and at cooling 
temperatures, but it is soluble in warm water (>40 ℃) (Yin et al. 2018). Thus, near 
physiological temperature, gelatin will be somewhat soluble and may not maintain the 
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structure. Unlike gelatin, the methacryloyl side groups on GelMA can undergo free 
radical polymerization in the presence of UV light and a photoinitiator; this capacity to 
chemically cross-link gives structural fidelity and on-demand morphing of the material. 
 
Previous cell viability studies showed that GelMA at a lower concentration (<5% 
w/v) was suitable for cell-laden bioinks and promote cell proliferation and survival (Liu 
et al. 2017; Yin et al. 2018; Colosi et al. 2016). However, GelMA at low concentrations 
poses problems with bioprinting due to its low viscosity, slow physical crosslinking rate, 
and inadequate mechanical strength (Yin et al. 2018). Adding gelatin into GelMA 
solution increases not only the viscosity but also the reversible physical gelation kinetics 
(Figure 6C). With gelatin in the bioink, the rheology of GelMA/gelatin bioink was easily 
modulated with temperature disturbance, and the shear-thinning property enhanced, all 
allowing for smooth fibrous bioprinting. From our results, a 5/5% GelMA/gelatin bioink 
showed the most printing compatibility at the room temperature. Moreover, it was shown 
that 5% (w/v) GelMA is suitable for cell scaffold as the pore sizes of the matrices is large 
enough for hosting cells (Yin et al. 2018). When using the 5/5% GelMA/gelatin bioink, 
the pore sizes of the matrices could be modulated by UV crosslinking the construct and 
then leaching out gelatin by submerging the construct in a heat bath. The UV crosslinking 
only occurs at the methacryloyl groups, and gelatin becomes soluble at high temperature. 
This way, the scaffolds printed from 5/5% GelMA/gelatin bioink is biocompatible, has 
high structural fidelity, and is cell-friendly.  
 34 
Furthermore, currently available cardiac monitoring devices present many 
downsides. The classic Holter monitor continuously records and transmits data; however, 
its function is limited by its short battery lifespan (two weeks maximum) and low patient 
compliance as the wearable device may be inconvenient for some daily activities such as 
exercise (Zimetbaum and Goldman 2010). Other event monitors may be more durable 
and convenient to wear, but are only recorded when triggered by the patient and may not 
record rare arrhythmias or abnormal cardiac activities (Zimetbaum and Goldman 2010). 
There are implantable loop recorders and pacemakers that can monitor the heart and are 
much more durable than external devices, but they require invasive surgery for 
implantation (Zimetbaum and Goldman 2010). With the advent of soft electronics, there 
is growing interest in novel bio-electronic devices (Lind et al. 2017; Yuk et al. 2016; 
Jeong et al. 2016). PDMS is a type of silicone rubber that is highly stretchable and 
flexible and is often used to encapsulate other materials to mechanically and chemically 
decouple them from their environment (Lötters et al. 1997). Its hydrophobicity and low 
chemical reactivity make it non-toxic and optimal for an electronics-carrier (Lötters et al. 
1997; Jeong et al. 2016). However, these properties also render it challenging to bind to 
other materials such as hydrogels. Surface modification of PDMS is one way to create a 
tight bonding between PDMS-based elastomers and hydrogels (Yuk et al. 2016). We 
have specifically modified the surface of a PDMS layer to introduce a cross-linkable 
polymer that can undergo free radical polymerization with the methacrylate group on 
GelMA. The surface modification has improved the hydrophilicity of the PDMS surface. 
The soft electronics-embedded elastomer and bioprinted-myocardium hydrogel hybrid 
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may provide a promising solution for challenges involving cardiac regeneration and 
monitoring. 
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CONCLUSIONS AND FUTURE WORK 
 
In summary, this work optimized the bioprinting conditions and bioink 
composition for 3D extrusion bioprinting of a myocardium construct. It was found that 
the extrusion pressures of 40 and 50 psi and the speed of an extrusion nozzle at around 
200 and 300 mm/min were optimal for bioprinting of the 5/5% GelMA/gelatin bioink at 
the room temperature. This study also showed how to modify the surface of an elastomer 
that potentially carries a soft electronics mesh such that the elastomer unit can be stably 
bound to the bioprinted cardiac construct.  
 
The mechanical characterization of GelMA/gelatin hydrogel blocks is currently 
ongoing: measuring the elasticity and compression by using a mechanical testing 
machine and measuring pore sizes by scanning electron microscope imaging. The 
bonding of hydrogel and elastomer will be tested using the same mechanical testing 
machine.  
 
In the future, endothelial cells will be included in the bioink formulation to 
produce a bioprinted endothelium that will be seeded with the cardiomyocytes. The 
construct will be bound to a soft electronics mesh embedded in the elastomer unit to 
generate a cardiac patch. The cardiac patch can be further used for regenerative medicine.  
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